Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PvCS/Montanide ISA-51 Vaccine Against P. Vivax Malaria
NCT07373301Phase 2Not yet recruiting
- Sponsor
- Malaria Vaccine and Drug Development Center
- Start
- Jan 2026
- Primary completion
- Jul 2027
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PvCS/Montanide ISA-51 VG in Plasmodium vivax malaria (4 arms), sponsored by Malaria Vaccine and Drug Development Center. Primary endpoint: Protective Efficacy Against P. vivax Infection After Controlled Human Malaria Infection (CHMI). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
PvCS/Montanide ISA-51 VG
03
Conditions
Plasmodium vivax malaria
Beyond the preview
Go deeper on NCT07373301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07373301.